Bristol-Myers Squibb Company (BMY) Return on equity 2016–2025
Bristol-Myers Squibb Company (BMY) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
38.2%FY2025 · since FY2016: 27.6% → 38.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 38.2% | +93.0 pp |
| FY2024 | -54.8% | -82.0 pp |
| FY2023 | 27.3% | +6.9 pp |
| FY2022 | 20.4% | +0.9 pp |
| FY2021 | 19.5% | +43.3 pp |
| FY2020 | -23.8% | -30.5 pp |
| FY2019 | 6.7% | -28.4 pp |
| FY2018 | 35.1% | +26.5 pp |
| FY2017 | 8.6% | -19.0 pp |
| FY2016 | 27.6% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice